---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-133525"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-12-05T23:59:59+00:00"
generated_at: "2026-05-29T07:22:28.804577+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa sets RP2D for MRT-2359 at 0.5 mg/day 21/7 schedule; safety, PD data positive

## Summary
- RP2D selected: 0.5 mg daily on 21-days-on/7-days-off schedule based on favorable safety and ~60% GSPT1 degradation.
- No hypotension, cytokine release syndrome, or clinically significant hypocalcemia observed at any dose.
- Doses ≥1.5 mg/day on 5/9 schedule exceeded MTD; thrombocytopenia was DLT; 0.5 and 1 mg were tolerable.
- Combination safety assessments started: MRT-2359 + enzalutamide in prostate cancer and + fulvestrant in breast cancer.
- Updated biomarker and activity data from Phase 1/2 study expected in Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-133525
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024133525/0000950170-24-133525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024133525/glue-20241205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-133525
- JSON: https://secwatch.observer/filing/0000950170-24-133525.json
- Plain text: https://secwatch.observer/filing/0000950170-24-133525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.